Royal Philips has announced the latest release of TissueMark, which now supports region of interest detection for the majority of molecular testing and helps research laboratories improve the accuracy of tumour estimation. The new version, which was showcased at the 30th European Congress of Pathology, leverages deep learning artificial intelligence (AI) to aid in prostate and ovarian tumour tissue identification.
Prostate cancer is the second deadliest cancer for men and ovarian cancer is the fifth deadliest for women. Given the severity of these two cancers, it is increasingly important that pathologists are equipped with the technology they need to further their research in these important areas. Innovative computational solutions can help pathologists improve efficiency in the research setting, which will ultimately help support precision medicine and enhance the speed and accuracy of diagnosis.
In addition to providing tumour sufficiency guidance for lung histology, lung cytology, colon and breast tissue samples in 60 seconds, the updated TissueMark software now provides this guidance to whole-slide images (WSI) of prostate adenocarcinoma and high-grade serous ovarian carcinoma.
